AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped ...

While some Americans might feel doubtful about prescriptions, others are doing all they can to acquire GLP-1 drugs. Carly ...

AbbVie (ABBV) stock gains as the company lifts 2025 earnings outlook after strong Q1 results, driven by its newer immunology ...

Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors immunotherapy treatment.

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics ...

A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (NYSE: ABBV) ...

Now, we may know why zombie skin cells have this double agent-esque existence. Not all senescent skin cells are the same.

Researchers from Johns Hopkins University have identified three subtypes of senescent skin cells with distinct shapes, ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.